trial

Reducing the Burden of Chronic Psychotic Disorders in Tanzania (CAPACITY)

NCTId NCT04327843
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 3 · Completed
Enrollment 22 (actual)
Sponsored by Case Western Reserve University
Primary completion 2020-07-30
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 3
Status
Completed
Enrollment
22 (actual)
Study type
Interventional
Allocation
Na
Model
Single Group
Masking
None
Start
2019-11-05
Primary completion
2020-07-30
Eligibility
ALL · 18 Years

Interventions & indications

Drugs
Customized Adherence EnhancementHaloperidol

Sponsors

Case Western Reserve UniversityLead Sponsor
National Institute of Mental Health (NIMH)Collaborator

Investigators

1
Martha Sajatovic, MDPrincipal Investigator

Sites

1 total
Dar es Salaam, Tanzania

Linked catalysts

1
Reducing the Burden of Chronic Psychotic Disorders in Tanzania (CAPACITY) — primary completion2020-07-30

Facts & assertions

4 sourced
Enrollment
22
Phase
PHASE3
Primary Completion Date
2020-07-30
Status
COMPLETED
relationships
The graph out of here
drug
Customized Adherence Enhancement
drug
Haloperidol
drug
lead_sponsor
Case Western Reserve University
company
collaborator
National Institute of Mental Health (NIMH)
company
indication
Schizo Affective Disorder
indication
Medication Adherence
indication
Psychotic Disorders
indication
investigator
Martha Sajatovic, MD
person